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Abstract
Background/Aims An open-label, multi-center, expanded
access study was conducted in patients with advanced
neuroendocrine tumors (NET) treated with everolimus
(10 mg/day) to assess safety and health-related quality
of life (HRQOL).
Methods Of the 246 patients enrolled, 126 have pancre-
atic NET (pNET) and 120 have non-pNET. Patients
continued treatment until disease progression, unaccept-
able toxicity, death, until commercial availability of
everolimus, or May 2012, whichever came first.
Adverse events (AEs) were analyzed according to
Common Terminology Criteria version 4.0. HRQOL
was assessed at baseline, for three 28-day cycles, and
then at every three cycles until end of treatment (EOT)
with EQ-5D, EORTC QLQ-C30, and EORTC QLQ-
GINET21 instruments.
Results The most common grade 3 or 4 AEs included hyper-
glycemia, infections, stomatitis, fatigue, and abdominal pain.
In patients with pNET, mean (± SD) EQ VAS score remained
stable at EOT (baseline, 68.8 ± 19.9 vs. EOT, 66.5 ± 20.6)
without clinically significant change in QLQ-C30 global
health status (change from baseline, - 3.9; n=86). For patients
with non-pNET, a reduction in EQ VAS score (63.9±19.0 vs.
55.3±23.0) with clinically significant changes in QLQ-C30
global health status (-13.0; n=69) was seen by EOT. EQ-5D
utility scores remained stable in patients with pNET and a
moderate decrease was reported by patients with non-pNET.
Conclusions The safety profile of everolimus was consistent
with the previous studies without adversely affecting HRQOL
in pNET. Lower baseline HRQOL scores and more frequent
comorbidities might have contributed to the worse outcomes
in non-pNET.
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Key Points
The findings of our study showed that the safety profile 
of everolimus was consistent with previous experience 
and revealed no new signals.
Patient-reported HRQOL remained stable in patients 
with pancreatic NET throughout the treatment period.
1 Introduction
Neuroendocrine tumors (NET) are rare malignant neoplasms
originating from diffuse neuroendocrine cells from various
sites throughout the body [1, 2]. NET are classified into pan-
creatic NET (pNET) or non-pancreatic NET (non-pNET),
based on their site of origin [3]. Surgical excision of the pri-
mary tumor and/or metastases is the only curative treatment
currently available for advanced NET; relapse following sur-
gery is common [4–6]. Although chemotherapy has some ef-
ficacy in pNET, it is not recommended for patients with slow-
ly progressive non-pNET due to limited efficacy and high
toxicity [7]. Other therapies, such as radiolabeled somatostatin
analogues (SSA), lack data from prospective, randomized
studies in patients with pNET demonstrating that benefits out-
weigh potential toxicities associated with treatment [8]. Novel
targeted agents such as everolimus, sunitinib, and SSA
(octreotide, lanreotide) have changed the treatment paradigm
for patients with NET [7].
The efficacy and safety of everolimus, an oral mTOR
inhibitor, in patients with advanced pNET as well as car-
cinoid tumors have been evaluated in large, multicenter,
double-blind, randomized, placebo-controlled, phase III tri-
als [9, 10]. Everolimus was approved for the treatment of
advanced pNET in 2011 in the United States and in the
European Union. An important goal of effective treatment
for patients with malignant diseases is to maintain quality
of life (QOL) in addition to preventing tumor progression.
Advanced NET is associated with a considerable health-
related QOL (HRQOL) burden, resulting not only from
the disease, but also due to the potential of experiencing
treatment-related adverse events (AEs) [11]. The impact of
everolimus on QOL in patients with NET has not been
previously reported.
An expanded access protocol (EAP) provided everolimus
access to patients with advanced NETwho lacked satisfactory
treatment alternatives before its regulatory approval and com-
mercial availability. Results presented herein focus on the ad-
ditional safety assessment of everolimus and the impact of
everolimus on HRQOL in patients with advanced NET during
the EAP.
2 Methods
2.1 Study Design and Patient Population
This was an open-label, multicenter, phase 3b expanded ac-
cess study of everolimus that enrolled patients from April 21,
2011 until April 20, 2012 (EudraCT no. 2010-023032-17).
Patients from 72 centers in nine countries worldwide
(Austria, Belgium, Czech Republic, Germany, Italy,
Republic of Korea, Saudi Arabia, Taiwan, and Thailand) were
recruited.
Adult patients (aged ≥ 18 years) with biopsy proven,
unresectable or metastatic NET, who had World Health
Organization performance status (WHO PS) 0 to 2, adequate
bone marrow, renal, and hepatic functions were eligible for
this study. Additional key eligibility criteria included fasting
serum total cholesterol level ≤300 mg/dL (≤7.75 mmol/L) and
fasting triglyceride level ≤2.5 times the upper limit of normal.
Key exclusion criteria included poorly differentiated NET,
cytotoxic chemotherapy, immunotherapy, or radiotherapy
within 4 weeks prior to enrollment, or prior therapy with
mTOR inhibitors (sirolimus, temsirolimus, or everolimus).
Enrollment of patients with advanced NET of GI or lung ori-
gin (non-pNET) was not allowed following protocol amend-
ment 1, September 6, 2011, based on the findings of the
RADIANT-2 study [9]. However, patients with non-pNET
enrolled in the study prior to the amendment continued in
the study.
All patients were screened for inclusion and exclusion
criteria within 5 weeks before the first dose of everolimus.
The screening evaluations included obtaining written in-
formed consent, a physical examination, demography, medi-
cal history and current medical conditions, current concomi-
tant medications and prior anticancer therapies, disease history
and extent of disease. Baseline evaluations (WHO PS, vital
signs, laboratory tests, HRQOL, and a serum pregnancy test,
if indicated) were performed within 2 weeks of the first evero-
limus dose.
Oral everolimus (two 5 mg tablets, totally 10 mg/day, in
28-day cycles) was taken by patients until disease progression,
unacceptable toxicity, death, discontinuation from the study
for any other reason, commercial availability for advanced
NET in each participating country (except the United
Kingdom and Norway), or May 30, 2012, whichever came
first. Patients were monitored at monthly clinic visits and
returned for an end-of-treatment visit 28 days after completion
of the study treatment period or discontinuation of medication.
Dose adjustments were permitted in patients who were un-
able to tolerate protocol-specified dosing of everolimus or for
those who experienced any AE suspected to be related to
everolimus: first to 5 mg/day and then to 5 mg every other
day. Dose reduction below 5 mg every other day was not
allowed. For patients with mild or moderate hepatic
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impairment (Child-Pugh class A or B), everolimus was ad-
ministered at 7.5 mg/day or 2.5 mg/day, respectively.
Management plans for everolimus-suspected toxicities
were provided to all the investigators. Such toxicities included
stomatitis, oral mucositis, and mouth ulcers; hyperlipidemia
and hyperglycemia; infections, noninfectious pneumonitis; re-
activation of hepatitis B and hepatitis C. Monitoring for pneu-
monitis was instituted upon the presentation of a patient with
nonspecific respiratory signs and symptoms that included
hypoxia, pleural effusion, cough, and dyspnea; patients were
advised to promptly report any new or worsening respiratory
symptoms.
2.2 Assessments
2.2.1 Safety and Tolerability
The primary objective of this study was to evaluate additional
safety of everolimus in patients with advanced pNET. The
occurrence of AEs was sought by non-directive questioning
of the patient during the screening and at each visit during the
study. AEs were also detected when patient volunteered for
their adverse symptoms or through physical examination, lab-
oratory test, or other assessments at different study visits. All
grade 3 or 4 AEs, serious AEs, and laboratory abnormalities of
Common Terminology Criteria (CTC) grade 3 or 4 were re-
corded. Grade 1 or 2 AEs or laboratory value or test procedure
abnormalities were not recorded unless they caused a study
drug dose modification or interruption.
2.2.2 Efficacy and HRQOL Assessments
The secondary objectives were efficacy (best overall response
and progression-free survival [PFS]) and assessment of
changes in HRQOL. For efficacy evaluation, tumor assess-
ments (by computed tomography or magnetic resonance im-
aging) were done at screening and repeated every 12 weeks
(±4 weeks) during the first year and every 6 months thereafter,
until discontinuation of the study drug or end of study. The
investigator-reported overall response (complete response
[CR], partial response [PR], stable disease [SD], or progres-
sive disease [PD]) as per the Response Evaluation Criteria in
Solid Tumors (RECIST; version 1.0) at each assessment was
used to derive the best overall response.
PFS was defined as the time from the date of first dose to
the date of the first documented disease progression or death
due to any cause. If a patient had not progressed or died at the
study end date or if he/she had received any further antineo-
plastic therapy, PFS was censored at the time of the last tumor
assessment before the study end date.
HRQOLwas assessed using EuroQOL-5Dimensions (EQ-
5D) questionnaire, European Organization for Research and
Treatment of Cancer Core Quality of Life Questionnaire
(EORTC QLQ)-C30 (version 3.0), and EORTC QLQ-
GINET21 (a specifically developed module of EORTC QLQ
for patients with GI-related NET) [12].
EQ-5D questionnaire comprises the EQ-5D descriptive
system and a visual analogue scale, the EQ VAS [13, 14].
The EQ-5D descriptive system consists of five dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression; each dimension having three levels of per-
ceived problems: no problems, some problems, or extreme
problems. For the EQ VAS, the respondents indicate their
overall self-rated health state on a scale ranging from 0 (worst
imaginable health state) to 100 (best imaginable health state).
The EORTC QLQ-C30 is a 30-item self-administered val-
idated questionnaire assessing physical, emotional, and social
health issues relevant to a broad spectrum of cancer patients,
with general population reference values for comparison [15].
The EORTC QLQ-GINET21 questionnaire contains 21 items
and is validated for use in patients with GI-related NET [16]. It
assesses disease symptoms, treatment effects, body image,
disease-related worries, social functioning, communication,
and sexual intimacy. Validated scores for EORTC QLQ-C30
and EORTCQLQ-GINET21 for patients with NET have been
published [12, 15]. For the EORTC QLQ-C30 and EORTC
QLQ-GINET21 scales, higher scores indicate better function-
ing, better QOL, or worse symptom levels; changes <10
points are not considered clinically significant.
The HRQOL was assessed at baseline and then at cycles 1,
2, and 3 (28-day intervals) during initial everolimus treatment,
and then once every three cycles (84-day intervals) until the
end of treatment. Patients were asked to complete EORTC
QLQ-GINET21 questionnaire after completing the EORTC
QLQ-C30. EQ-5D questionnaire was administered either be-
fore EORTCQLQ-C30 or after patient completed the EORTC
QLQ-GINET21 questionnaire.
2.3 Statistical Analyses
The safety population consisted of all patients who received at
least one dose of everolimus and had at least one post-baseline
safety assessment. For the safety assessments, AEs were cod-
ed using MedDRA version 14.0 and were graded using the
Common Terminology Criteria for Adverse Events (CTCAE)
version 4.0 [17]. If CTCAE grading did not exist for an AE,
grade 1 to 4 corresponding to the severity (mild, moderate,
severe, and life threatening) were used.
The full analysis set (FAS) was used for the analysis of
secondary objectives and included all patients who received
at least one dose of everolimus. The investigator-assessed
overall response (according to RECIST version 1.0) was used
to derive best overall response and was summarized in terms
of percentage rates.
Kaplan-Meier estimates of PFS with 95 % confidence in-
terval (CI) at specific time points were summarized. PFS was
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also analyzed according to the following subgroups: age (<65
or ≥65 years), gender (male or female), race (Caucasian,
Asian, or other), WHO PS (0 or >0), region (Europe or
Asia), liver involvement at baseline (at least one baseline tar-
get or non-target lesion in liver as per investigator, yes or no),
tumor histology (well-, moderately or poorly differentiated),
prior long-acting SSA use (yes or no), prior chemotherapy
(yes or no).
For HRQOL evaluation, the last value before treatment
discontinuation was used to summarize values of each
HRQOL scores at end of treatment. Descriptive statistics
(mean, standard deviation) were reported for each of the scale
scores at baseline and post-baseline visits.
3 Results
3.1 Patient Demographics
A total of 246 patients received at least one dose of everolimus
(FAS), including 126 patients with pNET and 120 with non-
pNET. Baseline demographics and disease characteristics of
patients are presented in Table 1.
Approximately one third of patients with pNET and 55 %
of those with non-pNET had functioning disease at presenta-
tion. In patients with non-pNET, most frequent primary tumor
sites were small intestine (n= 48; 40.0 %), lung (n= 26;
21.7 %), colon (n=10; 8.3 %), and other (n=21; 17.5 %).
Patients with pNET were younger, had a higher proportion
of patients with newly diagnosed disease (40 % of patients
with pNET had diagnosis within 2 years of study enrolment
vs. 26 % of patients with non-pNET).
Median duration of everolimus exposure was 12.1 and
24.0 weeks in patients with pNET and non-pNET, respective-
ly. All the patients discontinued the study treatment. The pri-
mary reason for discontinuation in both the pNET (67.5 %)
and non-pNET (36.7 %) groups was study termination by
sponsor following the final regulatory approval and commer-
cial availability of everolimus. The other reasons for treatment
discontinuation (pNET and non-pNET) were AEs (15.1 and
19.2 %), disease progression (11.1 and 21.7 %), consent with-
drawal (3.2 and 14.2 %), death (2.4 and 5.0 %), lost to follow-
up (0.8 and 1.7 %), protocol deviation (0 and 0.8 %), and
administrative problems (0 and 0.8 %), respectively. There
are only 17 patients (eight in pNET and nine in non-pNET
group) out of 240 patients who had a drug exposure of
<1 month.
3.2 Safety and Tolerability
Three patients from each group discontinued treatment before
any valid post-baseline assessments could be made and were
excluded from the safety assessment. The remaining 240
patients were included in the safety population; 123 with
pNET and 117 with non-pNET. In total, 15 patients died dur-
ing the study. Of these, five patients had pNET and remaining
10 had non-pNET (Table 2).
Four patients with pNET and nine with non-pNET died
while on treatment with everolimus; all deaths were deter-
mined by the investigator to be disease related. The most
frequent AEs are presented in Table 3.
Most commonly reported AEs were of grade 1 or 2. In the
pNET group, hyperglycemia, infections, stomatitis, and diar-
rhea were the most common drug-related grade 3 or 4 AEs,
whereas infections, diarrhea, fatigue, abdominal pain, and
general physical health deterioration were the most common
grade 3 or 4 AEs in the non-pNET group.
Table 1 Patient demographics and baseline characteristics (full
analysis set)
Characteristics pNET
(n = 126)
Non-pNET
(n= 120)
Age, years
Median 61 66
< 65, n (%) 74 (58.7) 50 (41.7)
≥ 65, n (%) 52 (41.3) 70 (58.3)
Sex, n (%)
Male 68 (54.0) 59 (49.2)
Female 58 (46.0) 61 (50.8)
Race, n (%)
White 91 (72.2) 119 (99.2)
Asian 34 (27.0) 1 (0.8)
Other 1 (0.8) 0 (0)
Functional status
Functioning 38 (30.2) 66 (55.0)
Nonfunctioning 88 (69.8) 54 (45.0)
Histology
Well-differentiated 81 (64.3) 65 (54.2)
Moderately differentiated 26 (20.6) 34 (28.3)
Poorly differentiated 1 (0.8) 2 (1.7)
Unknown/missing 16 (12.7)/2 (1.6) 19 (15.8)/0
Time since initial diagnosis, n (%)
≤ 2 years 50 (39.7) 31 (25.8)
> 2 to ≤ 5 years 27 (21.4) 26 (21.7)
> 5 years 21 (16.7) 26 (21.7)
Missing 28 (22.2) 37 (30.8)
WHO PS
0 70 (55.6) 63 (52.5)
1 47 (37.3) 46 (38.3)
2 8 (6.3) 10 (8.3)
Missing 1 (0.8) 1 (0.8)
Prior somatostatin analogues, no. (%) 82 (65.1 %) 85 (70.8)
NET neuroendocrine tumor, pNET pancreatic NET, WHO PS World
Health Organization performance status
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3.3 Efficacy
The median PFS, as assessed by the local investigators, was
7.6 months (95 % CI, 5.5-7.6) in patients with pNET and
10.8 months (95 % CI, 8.8-not estimable) for those with
non-pNET (Fig. 1).
Among patients with pNET, the median PFS was higher in
female patients (7.6 months vs. 5.6 months in male patients),
in patients with WHO PS of 0 (7.6 months vs. 5.6 months in
those who hadWHO status>0), and in patients with prior use
of SSA (7.6 months vs. 5.6 months for patients who did not
receive prior SSA).
For patients with non-pNET, the median PFS was higher in
those who had WHO PS of 0 (10.8 months vs. 8.8 months in
those who had WHO PS>0) and had no prior chemotherapy
(10.8 months vs. 9.5 months in patients with prior
chemotherapy).
Best overall response (investigator assessed) was PR
for two (1.6 %) patients in the pNET group and one
(0.8 %) in the non-pNET group. Disease stabilization
was the best overall response in 58.7 % of patients in
the pNET group and 70.0 % of the patients in the non-
pNET group. Nine (7.1 %) patients from the pNET
group and eight (6.7 %) patients from the non-pNET
group had progressive disease as the best outcome.
The response was unknown in 41 (32.5 %) and 27
(22.5 %) patients from pNET and non-pNET groups,
respectively.
3.4 Health-Related Quality of Life
3.4.1 EQ-5D
For patients with pNET, mean (±SD) EQ VAS and EQ-5D
utility scores remained stable at the end of treatment.
Patients with non-pNET had lower mean (±SD) EQ VAS
and EQ-5D utility scores at baseline and reported a moderate
decrease at the end of treatment (Table 4).
3.4.2 EORTC QLQ-C30
In patients with pNET, EORTC QLQ-C30 global health
status remained stable throughout the treatment period
with a mean change (±SD) of -3.9 points (±21.0) from
baseline to end of treatment. Patients with non-pNET
were less stable with respect to global health status,
with a mean change of -13.0 points (±28.1) from base-
line to end of treatment. For patients with pNET, no
clinically significant difference in EORTC QLQ-C30
global health status, functioning, or symptom scales
was found between baseline and at the end of treatment.
For patients with non-pNET, clinically significant mean
changes (>10 points) were observed in individual func-
tioning (i.e., physical, role, and social), symptom (i.e.,
fatigue and pain), and additional symptoms (loss of ap-
petite) scores at the end of treatment compared to the
baseline values (Fig. 2).
3.4.3 EORTC QLQ-GINET21
Individual measures of the EORTC QLQ-GINET21
remained stable from baseline to the end of treatment,
and none was considered clinically significant according
to the criteria from previous validation studies conduct-
ed for this instrument [16]; except for body image, for
which the change from baseline to end of treatment was
>10 points in non-pNET (Fig. 3).
4 Discussion
Everolimus is a cornerstone for the treatment of patients with
advanced pNET. The safety profile of everolimus in this EAP
study was similar to the known safety profile for the drug in
patients with advanced NET. Although AEs observed with
everolimus treatment were similar in type to those previously
reported, incidence was lower. This difference may be attrib-
uted to the methods used to report AE in this study or to the
shorter duration of everolimus exposure compared with the
earlier studies [9, 10].
The present study also evaluated the efficacy of
everolimus in patients with advanced NET using
Table 2 Summary of deaths and adverse events
AE category, n (%) pNET
n= 123
Non-
pNET
n= 117
All deaths 5 (4.1) 10 (8.5)
On-treatment deathsa 4 (3.3) 9 (7.7)
All reported AEs 90 (73.2) 109 (93.2)
Suspected to be drug related 64 (52.0) 87 (74.4)
Grade 3 or 4 52 (42.3) 81 (69.2)
Suspected to be drug related 28 (22.8) 52 (44.4)
SAEs 25 (20.3) 59 (50.4)
Suspected to be drug related 7 (5.7) 26 (22.2)
AEs leading to discontinuation 21 (17.1) 29 (24.8)
Suspected to be drug related 13 (10.6) 19 (16.2)
AEs requiring dose interruption and/or reduction 48 (39.0) 62 (53.0)
AEs requiring additional therapyb 58 (47.2) 87 (74.4)
a On-treatment deaths are deaths that occurred up to 28 days after discon-
tinuation of study treatment. AEs occurring >28 days after discontinua-
tion of study treatment are not summarized
b Additional therapy includes all non-drug therapies and concomitant
medications
AEs adverse events, pNET pancreatic neuroendocrine tumors, SAEs seri-
ous adverse events
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Table 3 Adverse events
occurring in at least 5 % of
patients irrespective of
relationship to study drug (safety
analysis set)
Adverse event pNET
(n= 123)
Non-pNET
(n = 117)
All grades
n (%)
Grade 3
n (%)
Grade 4
n (%)
All grades
n (%)
Grade 3
n (%)
Grade 4
n (%)
Stomatitisa 29 (23.6) 6 (4.9) 0 22 (18.8) 3 (2.6) 0
Infectionsb 25 (20.3) 7 (5.7) 1 (0.8) 45 (38.5) 19 (16.2) 3 (2.6)
Hyperglycemia 15 (12.2) 8 (6.5) 0 6 (5.1) 4 (3.4) 0
Diarrhea 13 (10.6) 5 (4.1) 0 37 (31.6) 9 (7.7) 1 (0.9)
Asthenia 12 (9.8) 3 (2.4) 0 7 (6.0) 3 (2.6) 1 (0.9)
Thrombocytopenia 12 (9.8) 1 (0.8) 0 6 (5.1) 2 (1.7) 0
Pyrexia 10 (8.1) 2 (1.6) 0 8 (6.8) 0 0
Rash 10 (8.1) 1 (0.8) 0 8 (6.8) 2 (1.7) 0
Nausea 10 (8.1) 0 0 12 (10.3) 3 (2.6) 0
Anemia 7 (5.7) 3 (2.4) 1 (0.8) 13 (11.1) 4 (3.4) 0
Decreased appetite 7 (5.7) 2 (1.6) 0 10 (8.5) 3 (2.6) 0
Hypertension 5 (4.1) 2 (1.6) 0 6 (5.1) 2 (1.7) 0
Edema peripheral 5 (4.1) 2 (1.6) 0 16 (13.7) 1 (0.9) 1 (0.9)
Abdominal pain 5 (4.1) 0 0 12 (10.3) 8 (6.8) 0
Headache 4 (3.3) 0 0 9 (7.7) 2 (1.7) 0
Vomiting 3 (2.4) 1 (0.8) 0 6 (5.1) 2 (1.7) 0
General physical health
deterioration
2 (1.6) 2 (1.6) 0 9 (7.7) 4 (3.4) 3 (2.6)
Hypokalemia 2 (1.6) 1 (0.8) 0 6 (5.1) 4 (3.4) 0
Pulmonary eventsc 2 (1.6) 0 0 6 (5.1) 0 2 (1.7)
Fatigue 1 (0.8) 0 0 17 (14.5) 8 (6.8) 1 (0.9)
pNET pancreatic neuroendocrine tumor
a Included in this category are mucosal inflammation, stomatitis, aphthous stomatitis, mouth ulceration, and
gingival pain
b All types of infections are included
c Included in this category are pneumonitis, interstitial lung disease, and lung infiltration
Patients still at risk, n
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investigator-assessed PFS and best overall response.
Everolimus was effective in stabilizing disease and
preventing disease progression in the majority of pa-
tients with pNET and non-pNET. The PFS results
should be interpreted cautiously due to early termination
of the study.
Overall, quality of life was maintained during the
treatment with everolimus in patients with pNET.
Table 4 EQ VAS and EQ-5D
utility scores Scale pNET (n= 126) Non-pNET (n= 120)
Baseline End of treatment Baseline End of treatment
EQ VAS
n
Mean (SD)
118
68.8 (19.9)
86
66.5 (20.6)
111
63.9 (19.1)
76
55.3 (23.0)
EQ-5D utility score
n
Mean (SD)
115
0.741 (0.276)
80
0.733 (0.293)
110
0.705 (0.259)
75
0.561 (0.359)
pNET pancreatic neuroendocrine tumor, SD standard deviation
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Fig. 2 Change from baseline to
end of treatment (last value before
treatment discontinuation) in
QLQ-C30 (full analyses set).
Higher values indicate greater
functioning, greater quality of
life, or worse symptom levels; a
change of <10 points is not
considered clinically significant.
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impact. n number of patients who
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However, NET-specific subscales from EORTC QLQ-
C30 and GINET21 showed worsening of some aspects
of individual functioning and disease-related symptoms
in the non-pNET study population. The worsening in
QOL could be attributed to comorbidities related to
the carcinoid syndrome as majority of non-pNET pa-
tients had intestinal tumors and, as expected, a higher
proportion of patients had functioning tumors at study
entry. Diarrhea and abdominal pain are features of the
carcinoid syndrome and were more frequent in the non-
pNET group and might have contributed to impaired
QOL at baseline, as well as worsening while on study.
Further, patients with non-pNET had a longer follow-up
and duration of therapy that could have negatively im-
pacted QOL due to cumulative side effects over a peri-
od of time. Infections, for instance, were more frequent
AEs in this group and might have contributed to decline
the health status in non-pNET group. In addition, a
higher number of patients in non-pNET group were
above 65 years, and this could have also resulted in
the worsening of HRQOL.
Duration of everolimus exposure for individual patient
could potentially impact the change in HRQOL and symp-
toms. However, patients in our study were on everolimus
treatment for a shorter period of time in contrast with the large
placebo- controlled trials (RADIANT-2 and −3), due to differ-
ent study design. After termination of the study, patients con-
tinued on drug outside of the study. Thus, an analysis of
HRQOL in relation to drug exposure was not feasible.
It is important to note that compared with a general popu-
lation reference sample [16], both the pNET and the non-
pNET groups in this study had worse global health, physical
functioning, role functioning, social functioning, appetite
loss, and diarrhea at baseline. This observation poten-
tially suggests that the patients included in this study
had more advanced disease compared to the other pop-
ulations for which QOL measures have been reported
[12, 15, 16]. With limited QOL data in patients with
NET from randomized clinical trials, caution is warrant-
ed in interpreting the results from this expanded access
study. While a specific QOL questionnaire for patients
with pNET is still lacking, future clinical studies will
provide more robust data on QOL of patients with
NET following treatment with everolimus.
In conclusion, the EAP study provided everolimus to pa-
tients with advanced pNET who were without satisfactory
treatment alternatives prior to regulatory approval and allowed
enrolment of non-pNET. Everolimus was well tolerated and
the safety profile in this study is in line with that reported from
earlier studies. Everolimus was effective in stabilizing disease
and preventing progression in the majority of patients.
Everolimus maintained patient-reported HRQOL in patients
with pNET throughout the treatment period as assessed by the
EQ-5D, EORTC QLQ-C30, and EORTC QLQ-GINET21
questionnaires. However, in the non-pNET group some of
the HRQOL subscale scores showed worsening in QOL.
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